Skip to content
Screener

Bicara Therapeutics BCAX Operating Lease Liabilities (Current)

Operating Lease Liabilities (Current) at other companies

ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$99K-28.3%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$13M+8.3%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$2.41M+22.0%
Immunome logo
ImmunomeIMNM
$152K—
Summit Therapeutics logo
Summit TherapeuticsSMMT
$3.18M-10.3%
Tyra Biosciences, Inc. logo
Tyra Biosciences, Inc.TYRA
$488K+14.6%

Other financials

Income statement

See full
Operating income-$60.2M-44.2%
Net income-$56.2M-52.6%
EPS (diluted)-$0.93-36.8%

Balance sheet

See full
Cash & equivalents$323.5M-30.0%
Total debt$1.4M+144%
Total equity$514.0M+12.0%
Total assets$553.6M+15.8%

Cash flow

See full
Operating cash flow-$37.5M-33.5%
CapEx$60.0K—
Free cash flow-$37.6M-33.7%

Valuation

See full
Market cap$1.84B+238%
Enterprise value$1.52B+1,278%

Returns & leverage

See full
Return on equity-32.3%—
Debt / equity0×0.0×
Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.

The source filing: Bicara Therapeutics’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 4:03 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-033429
Line itemMarch 31, 2026December 31, 2025
Accounts payable – related party1,2522,278
Accrued expenses and other current liabilities29,94818,898
Accrued expenses and other current liabilities – related party8121,141
Operating lease liability – current portion1,1401,117
Total current liabilities39,34028,949
Operating lease liability – net of current portion301593
Total liabilities39,64129,542
Commitments and Contingencies (Note 7)

Item 1. Financial Statements (Unaudited)

FAQ

What is Bicara Therapeutics's operating lease liabilities (current)?
Bicara Therapeutics (BCAX) reported operating lease liabilities (current) of $1.14M in Q1 2026.
How has Bicara Therapeutics's operating lease liabilities (current) changed year-over-year?
Bicara Therapeutics's operating lease liabilities (current) increased by 92.9% year-over-year, from $591K to $1.14M.
What is the long-term trend for Bicara Therapeutics's operating lease liabilities (current)?
Over 2 years (2023 to 2025), Bicara Therapeutics's operating lease liabilities (current) has grown at a 98.0% compound annual growth rate (CAGR), from $285K to $1.12M.
What does operating lease liabilities (current) mean?
The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.

Ask your AI about Bicara Therapeutics's operating lease liabilities (current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude